BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CCMG | CCGM - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CCMG | CCGM
X-ORIGINAL-URL:https://ccmg.51-222-78-205.ygkweb.ca
X-WR-CALDESC:Events for CCMG | CCGM
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250131T120000
DTEND;TZID=America/Toronto:20250131T130000
DTSTAMP:20260628T171039
CREATED:20250114T170054Z
LAST-MODIFIED:20250114T170143Z
UID:10000057-1738324800-1738328400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \n2024-2025 Leading Strand from 12:00pm – 1:00pm ET\, scheduled dates are: \nFriday September 27\, 2024 \nFriday October 25\, 2024 \nFriday November 22\, 2024 \nFriday December 13\, 2024 – cancelled \nFriday\, January 31\, 2025 \nLiver-Directed Gene Therapy for Inherited Metabolic Disorders \nLearning objectives: \n\nQuote the most commonly used vectors for liver-directed gene therapy.\nAssess the safety and efficacy of gene therapy\, especially for inherited metabolic diseases.\nUnderstand the current limitations and issues of liver-directed gene therapy.\n\nDescription of talk: \nInherited metabolic diseases (IMD) are disorders affecting human biochemical pathways and represent attractive targets for gene therapy because of their severity\, high overall prevalence\, lack of effective treatments\, and possibility of early diagnosis through newborn screening. The liver is a central organ involved in several metabolic reactions and is a favorite target for gene therapy in many IMD. Adeno-associated virus (AAV) vectors have emerged in the last years as the preferred vectors for in vivo gene delivery. Gene replacement strategies are aimed either at correcting liver disease or providing a source for production and secretion of the lacking enzyme for cross-correction of other tissues. A number of preclinical studies have been conducted in the last two decades and\, for several diseases\, gene therapy has reached the clinical stage. In my talk\, our experience on two ongoing clinical gene therapy trials for IMD and I will highlight current obstacles and future strategies to overcome them. \nSpeaker: Dr. Nicola Brunetti \nBio: \nNicola Brunetti-Pierri graduated in Medicine and trained in Pediatrics at University of Naples Federico II. He then moved to Baylor College of Medicine\, Houston\, TX for a post-doctoral fellowship and clinical training in Medical Genetics and Biochemical Genetics. He was assistant professor in the Department of Molecular and Human Genetics of Baylor College of Medicine until he returned to Italy. As a physician-scientist his research goals are to elucidate the pathogenetic mechanisms and develop effective therapies for genetic diseases. He identified several new genetic diseases and generated proof-of-concept studies for new therapies in genetic disorders. He received awards from ASGCT and ESGCT and fundings by NIH and ERC. He is the principal investigator of phase 1/2 gene therapy clinical trials. He is Professor of Pediatrics at Federico II University of Naples\, Principal Investigator at the Telethon Institute of Genetics and Medicine (TIGEM)\, Italy. \nFriday February 28\, 2025 \nFriday\, March 28\, 2025 \nFriday\, April 25\, 2025 \nFriday\, May 30\, 2025 \nFriday June 27\, 2025 \nFriday\, May 16\, 2025 \nFriday\, June 20\, 2025
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-3-5/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
END:VCALENDAR